Trial Profile
An Open Label Extension Study to Assess the Safety of Long-Term Treatment With a 4 mL Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs DMI 9523 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Registrational
- Sponsors Ampio Pharmaceuticals
- 18 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 07 Nov 2018 Results presented in the Ampio media release.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting,According to an Ampio media release